Find Pemvidutide manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Alt801, Glxc-26955, 2538014-94-5
Molecular Formula
C178H270N38O53
Molecular Weight
3790  g/mol
InChI Key
PNRXPXQSTNKDJB-VGUJMDGVSA-N

Pemvidutide
1 2D Structure

Pemvidutide

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
18-[(2R,3R,4S,5S,6S)-6-[[(5S)-6-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-2-methylpropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-6-oxohexyl]carbamoyl]-3,4,5-trihydroxyoxan-2-yl]oxyoctadecanoic acid
2.1.2 InChI
InChI=1S/C178H270N38O53/c1-15-97(8)142(173(264)199-117(64-69-134(183)224)158(249)206-128(84-106-88-188-112-50-37-36-49-110(106)112)167(258)202-122(78-95(4)5)162(253)200-121(77-94(2)3)161(252)197-118(65-70-135(184)225)160(251)215-143(100(11)219)149(185)240)214-170(261)127(81-103-47-33-30-34-48-103)204-159(250)120(67-72-139(231)232)196-155(246)114(51-38-41-73-179)193-151(242)99(10)191-150(241)98(9)192-154(245)113(53-40-43-75-187-175(266)148-146(238)145(237)147(239)176(269-148)268-76-44-28-26-24-22-20-18-16-17-19-21-23-25-27-35-54-137(227)228)194-157(248)119(66-71-138(229)230)198-168(259)129(86-140(233)234)207-163(254)123(79-96(6)7)201-164(255)124(82-104-55-59-108(221)60-56-104)203-156(247)115(52-39-42-74-180)195-171(262)131(91-217)210-165(256)125(83-105-57-61-109(222)62-58-105)205-169(260)130(87-141(235)236)208-172(263)132(92-218)211-166(257)126(80-102-45-31-29-32-46-102)209-174(265)144(101(12)220)213-136(226)90-189-153(244)116(63-68-133(182)223)212-177(267)178(13,14)216-152(243)111(181)85-107-89-186-93-190-107/h29-34,36-37,45-50,55-62,88-89,93-101,111,113-132,142-148,176,188,217-222,237-239H,15-28,35,38-44,51-54,63-87,90-92,179-181H2,1-14H3,(H2,182,223)(H2,183,224)(H2,184,225)(H2,185,240)(H,186,190)(H,187,266)(H,189,244)(H,191,241)(H,192,245)(H,193,242)(H,194,248)(H,195,262)(H,196,246)(H,197,252)(H,198,259)(H,199,264)(H,200,253)(H,201,255)(H,202,258)(H,203,247)(H,204,250)(H,205,260)(H,206,249)(H,207,254)(H,208,263)(H,209,265)(H,210,256)(H,211,257)(H,212,267)(H,213,226)(H,214,261)(H,215,251)(H,216,243)(H,227,228)(H,229,230)(H,231,232)(H,233,234)(H,235,236)/t97-,98-,99-,100+,101+,111-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,142-,143-,144-,145-,146-,147+,148-,176+/m0/s1
2.1.3 InChI Key
PNRXPXQSTNKDJB-VGUJMDGVSA-N
2.1.4 Canonical SMILES
CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(C(C)O)C(=O)N)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCCCNC(=O)C4C(C(C(C(O4)OCCCCCCCCCCCCCCCCCC(=O)O)O)O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(C)(C)NC(=O)C(CC8=CNC=N8)N
2.1.5 Isomeric SMILES
CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCNC(=O)[C@@H]4[C@H]([C@@H]([C@H]([C@@H](O4)OCCCCCCCCCCCCCCCCCC(=O)O)O)O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)C(C)(C)NC(=O)[C@H](CC8=CNC=N8)N
2.2 Synonyms
2.2.1 Depositor-Supplied Synonyms

1. Alt801

2. Glxc-26955

3. 2538014-94-5

2.3 Create Date
2023-03-27
3 Chemical and Physical Properties
Molecular Weight 3790 g/mol
Molecular Formula C178H270N38O53
XLogP3-7.4
Hydrogen Bond Donor Count51
Hydrogen Bond Acceptor Count57
Rotatable Bond Count131
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area1500
Heavy Atom Count269
Formal Charge0
Complexity8720
Isotope Atom Count0
Defined Atom Stereocenter Count34
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Drugs in Development

read-more
read-more

Details:

ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. It is being evaluated for the treatment of obesity.


Lead Product(s): Pemvidutide

Therapeutic Area: Nutrition and Weight Loss Brand Name: ALT-801

Study Phase: Phase IIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 07, 2024

blank

01

Altimmune

U.S.A
arrow
SCOPE Summit
Not Confirmed

Altimmune

U.S.A
arrow
SCOPE Summit
Not Confirmed

Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. It is being evaluated for the treatment of obesity.

Product Name : ALT-801

Product Type : Peptide

Upfront Cash : Not Applicable

November 07, 2024

blank

Details:

ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis.


Lead Product(s): Pemvidutide

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: ALT-801

Study Phase: Phase IIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 30, 2024

blank

02

Altimmune

U.S.A
arrow
SCOPE Summit
Not Confirmed

Altimmune

U.S.A
arrow
SCOPE Summit
Not Confirmed

Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis.

Product Name : ALT-801

Product Type : Peptide

Upfront Cash : Not Applicable

September 30, 2024

blank

Details:

ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis.


Lead Product(s): Pemvidutide

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: ALT-801

Study Phase: Phase IIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 28, 2024

blank

03

Altimmune

U.S.A
arrow
SCOPE Summit
Not Confirmed

Altimmune

U.S.A
arrow
SCOPE Summit
Not Confirmed

Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis.

Product Name : ALT-801

Product Type : Peptide

Upfront Cash : Not Applicable

March 28, 2024

blank

Details:

ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. It is being evaluated for the treatment of obesity.


Lead Product(s): Pemvidutide

Therapeutic Area: Nutrition and Weight Loss Brand Name: ALT-801

Study Phase: Phase IIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 29, 2023

blank

04

Altimmune

U.S.A
arrow
SCOPE Summit
Not Confirmed

Altimmune

U.S.A
arrow
SCOPE Summit
Not Confirmed

Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. It is being evaluated for the treatment of obesity.

Product Name : ALT-801

Product Type : Peptide

Upfront Cash : Not Applicable

November 29, 2023

blank

Details:

ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.


Lead Product(s): Pemvidutide

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: ALT-801

Study Phase: Phase IIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 26, 2023

blank

05

Altimmune

U.S.A
arrow
SCOPE Summit
Not Confirmed

Altimmune

U.S.A
arrow
SCOPE Summit
Not Confirmed

Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.

Product Name : ALT-801

Product Type : Peptide

Upfront Cash : Not Applicable

October 26, 2023

blank

Details:

ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.


Lead Product(s): Pemvidutide

Therapeutic Area: Nutrition and Weight Loss Brand Name: ALT-801

Study Phase: Phase IIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 12, 2023

blank

06

Altimmune

U.S.A
arrow
SCOPE Summit
Not Confirmed

Altimmune

U.S.A
arrow
SCOPE Summit
Not Confirmed

Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.

Product Name : ALT-801

Product Type : Peptide

Upfront Cash : Not Applicable

September 12, 2023

blank

Details:

ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcoholic steatohepatitis (NASH).


Lead Product(s): Pemvidutide

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: ALT-801

Study Phase: Phase IIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 01, 2023

blank

07

Altimmune

U.S.A
arrow
SCOPE Summit
Not Confirmed

Altimmune

U.S.A
arrow
SCOPE Summit
Not Confirmed

Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcoholic steatohepatitis (NASH).

Product Name : ALT-801

Product Type : Peptide

Upfront Cash : Not Applicable

August 01, 2023

blank

Details:

ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss.


Lead Product(s): Pemvidutide

Therapeutic Area: Nutrition and Weight Loss Brand Name: ALT-801

Study Phase: Phase IIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 21, 2023

blank

08

Altimmune

U.S.A
arrow
SCOPE Summit
Not Confirmed

Altimmune

U.S.A
arrow
SCOPE Summit
Not Confirmed

Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of d...

Product Name : ALT-801

Product Type : Peptide

Upfront Cash : Not Applicable

March 21, 2023

blank

Details:

ALT-801 (pemvidutide), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.


Lead Product(s): Pemvidutide

Therapeutic Area: Nutrition and Weight Loss Brand Name: ALT-801

Study Phase: Phase IIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 20, 2022

blank

09

Altimmune

U.S.A
arrow
SCOPE Summit
Not Confirmed

Altimmune

U.S.A
arrow
SCOPE Summit
Not Confirmed

Details : ALT-801 (pemvidutide), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.

Product Name : ALT-801

Product Type : Peptide

Upfront Cash : Not Applicable

December 20, 2022

blank

Details:

ALT-801 (pemvidutide) is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH).


Lead Product(s): Pemvidutide

Therapeutic Area: Nutrition and Weight Loss Brand Name: ALT-801

Study Phase: Phase IIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 28, 2022

blank

10

Altimmune

U.S.A
arrow
SCOPE Summit
Not Confirmed

Altimmune

U.S.A
arrow
SCOPE Summit
Not Confirmed

Details : ALT-801 (pemvidutide) is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH).

Product Name : ALT-801

Product Type : Peptide

Upfront Cash : Not Applicable

October 28, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty